Phase 2 randomized studies with an expanded sample size are planned for 2025 to further evaluate the efficacy and safety of DNG64+ and to correlate CCNG1 expression level and circulating tumor DNA (ctDNA) level with treatment outcome parameters in response to DNG64+ gene therapy. The gene discussed is CCNG1; the disease is neoplasm.